Inscrição na biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicou 6 edições por ano

ISSN Imprimir: 0743-4863

ISSN On-line: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Targeted Breast Cancer Nanotherapeutics: Options and Opportunities with Estrogen Receptors

Volume 29, Edição 5, 2012, pp. 421-446
DOI: 10.1615/CritRevTherDrugCarrierSyst.v29.i5.20
Get accessGet access

RESUMO

Breast cancer is a multifarious and heterogeneous disease. Identification of molecular alterations of surface/intracellular proteins particularly involved in proliferation and growth of breast cancer cells provides opportunities for the development of new targets for therapy. Several ligands that are routinely employed in targeted delivery to breast cancer cells have been found to be immunogenic. Therefore, endogenous bioligands may serve as a better option, which may be bio-competent and non-immunogenic, including estrogens. Membrane-associated estrogen binding sites are highly over-expressed in cancers of endocrine origin, such as breast. The selective high density of these receptor portals can be utilized for targeted breast cancer therapy. Numerous estrogen−chemotherapeutic agent conjugates have been successfully utilized for targeted drug/DNA delivery. Recently, nanocarrier(s) anchored with estrogens as site-directing ligands for the delivery of bioactive(s) have been exhaustively investigated for breast cancer therapy. This review presents a detail account of how estrogens, anti-estrogens, and their derivatives can be used for site-specific delivery of bioactive(s) to breast cancer cells. The sequential emergence of various estrogen−anticancer drug conjugates is highlighted. Additionally, carrier systems that utilize estrogens/anti-estrogens as ligands for purpose-specific site-selective novel drug delivery platforms have been reviewed and revisited in terms of their realistic clinical applications in breast cancer treatment.

CITADO POR
  1. Yin Juan-Juan, Zhou Zhi-Wei, Zhou Shu-Feng, Cyclodextrin-based targeting strategies for tumor treatment, Drug Delivery and Translational Research, 3, 4, 2013. Crossref

  2. Markoutsa E., Papadia K., Giannou A. D., Spella M., Cagnotto A., Salmona M., Stathopoulos G. T., Antimisiaris S. G., Mono and Dually Decorated Nanoliposomes for Brain Targeting, In Vitro and In Vivo Studies, Pharmaceutical Research, 31, 5, 2014. Crossref

  3. Madan Jitender, Gundala Sushma R., Kasetti Yoganjaneyulu, Bharatam Prasad V., Aneja Ritu, Katyal Anju, Jain Upendra K., Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy, Anti-Cancer Drugs, 25, 6, 2014. Crossref

  4. Dissanayake Shama, Denny William A, Gamage Swarna, Sarojini Vijayalekshmi, Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides, Journal of Controlled Release, 250, 2017. Crossref

  5. Paliwal Rishi, Paliwal Shivani Rai, Kenwat Rameshroo, Kurmi Balak Das, Sahu Mukesh Kumar, Solid lipid nanoparticles: a review on recent perspectives and patents, Expert Opinion on Therapeutic Patents, 30, 3, 2020. Crossref

  6. Kunjiappan Selvaraj, Pavadai Parasuraman, Vellaichamy Sivakumar, Ram Kumar Pandian Sureshbabu, Ravishankar Vigneshwaran, Palanisamy Ponnusamy, Govindaraj Saravanan, Srinivasan Gowshiki, Premanand Adhvitha, Sankaranarayanan Murugesan, Theivendren Panneerselvam, Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: A state‐of‐the‐art review, Drug Development Research, 82, 3, 2021. Crossref

  7. Chand Pallavi, Kumar Hitesh, Badduri Nihal, Gupta N. Vishal, Bettada Vidya G., Madhunapantula SubbaRao V., Kesharwani Siddharth S., Dey Surajit, Jain Vikas, Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines, Colloids and Surfaces B: Biointerfaces, 199, 2021. Crossref

  8. Paliwal Rishi, Paliwal Shivani Rai, Controlled Delivery of Chemopreventive Agents, in Advances in Nanochemoprevention, 2020. Crossref

  9. Liu Weiwei, Ji Yachao, Sun Yu, Si Lingling, Fu Jianing, Hayashi Toshihiko, Onodera Satoshi, Ikejima Takashi, Estrogen receptors participate in silibinin-caused nuclear translocation of apoptosis-inducing factor in human breast cancer MCF-7 cells, Archives of Biochemistry and Biophysics, 689, 2020. Crossref

  10. Yang Huan, Tang Cui, Yin Chunhua, Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer, Acta Biomaterialia, 73, 2018. Crossref

  11. Paliwal Rishi, Sulakhiya Kunjbihari, Paliwal Shivani Rai, Singh Vijay, Kenwat Rameshroo, Paramanik Debashish, Role of nanoparticles in neurotoxicity, in Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022. Crossref

  12. Gajbe Bharti, Das Kurmi Balak, Kenwat Rameshroo, Paliwal Rishi, Paliwal Shivani Rai, Breast cancer: introduction, in Targeted Nanomedicine for Breast Cancer Therapy, 2022. Crossref

  13. Malaiya Akanksha, Singhai Mansha, Paliwal Shivani Rai, Paliwal Rishi, Basics of targeted nanodrug delivery of chemotherapeutics for breast cancer therapy, in Targeted Nanomedicine for Breast Cancer Therapy, 2022. Crossref

  14. Kenwat Rameshroo, Paliwal Shivani Rai, Paliwal Rishi, Targeted breast cancer nanotheranostics, in Targeted Nanomedicine for Breast Cancer Therapy, 2022. Crossref

  15. Li Weinan, Gong HeXin, Fu Yuhan, Sun Jialin, Wang Yanhong, Novel pH-sensitive nanoparticles based on prodrug strategy to delivery All-Trans Retinoic Acid for breast cancer, Colloids and Surfaces B: Biointerfaces, 219, 2022. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain